Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12611220 | 1.00 | DPP4 (0.38) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL801060 | 1.00 | DPP4 (0.38) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL860138 | 0.94 | NOS2 (0.43) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL800609 | 0.94 | NOS2 (0.43) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL14296385 | 0.94 | NOS2 (0.43) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL10037272 | 0.87 | NOS3 (0.37) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL19844516 | 0.87 | NOS3 (0.37) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL19844511 | 0.87 | NOS3 (0.37) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL27859825 | 0.79 | NOS2 (0.42) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL25096659 | 0.78 | DPP4 (0.39) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174282-B2 | Aminosteroid derivatives and process for producing same | UNIVERSITé LAVAL (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-9381200-B2 | Nitrogen containing compounds | WOCKHARDT LIMITED (IN) | 2016-07-05 | — | — | US | disclosed |
| US-20150328201-A1 | NITROGEN CONTAINING COMPOUNDS | WOCKHARDT LIMITED (IN) | 2015-11-19 | — | — | US | disclosed |
| US-9132133-B2 | Nitrogen containing compounds | WOCKHARDT LTD. (IN) | 2015-09-15 | — | — | US | disclosed |
| US-20150174133-A1 | NITROGEN CONTAINING COMPOUNDS | WOCKHARDT LIMITED (IN) | 2015-06-25 | — | — | US | disclosed |
| US-8987297-B2 | Nitrogen containing compounds | WOCKHARDT LTD. (IN) | 2015-03-24 | — | — | US | disclosed |
| US-20150005285-A1 | Nitrogen containing compounds | WOCKHARDT LIMITED (IN) | 2015-01-01 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090105122-A1 | Selective neuropeptide y2 receptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105122-A1 | Selective neuropeptide y2 receptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174133-A1 | NITROGEN CONTAINING COMPOUNDS | NOS2, NOS1, NCF1 | DPP4 3717/4885DPP8 3804/4885DPP9 2965/4885 |
| US-20150005285-A1 | Nitrogen containing compounds | NOS2, NOS1, NCF1 | DPP4 3717/4885DPP8 3804/4885DPP9 2965/4885 |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | DPP4 179/4885DPP8 281/4885DPP9 266/4885 |
| US-20090105122-A1 | Selective neuropeptide y2 receptor agonists | NPY2R, NPY1R, NPY4R | DPP4 261/4885DPP8 492/4885DPP9 670/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | DPP4 887/4885DPP8 681/4885DPP9 1431/4885 |
| US-20150328201-A1 | NITROGEN CONTAINING COMPOUNDS | NOS2, NOS1, NCF1 | DPP4 3717/4885DPP8 3804/4885DPP9 2965/4885 |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | MKI67, CCNC, CCNI | DPP4 4365/4885DPP8 4519/4885DPP9 4666/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DPP4 308/4885DPP8 335/4885DPP9 267/4885 |
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | TFPI, TFPI2, ADAMTS1 | DPP4 175/4885DPP8 77/4885DPP9 80/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | DPP4 2623/4885DPP8 2675/4885DPP9 2173/4885 |
| US-11174282-B2 | Aminosteroid derivatives and process for producing same | HSD17B11, HSD17B7, CYP19A1 | DPP4 1858/4885DPP8 1834/4885DPP9 2487/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | DPP4 2623/4885DPP8 2675/4885DPP9 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.